PDAC organoid pharmacotyping
Growing a patient's pancreatic tumour as mini-organs in a dish and testing chemotherapies on them to pick the regimen most likely to work.
Tuveson (CSHL) and others established PDAC organoids with transcriptomic signatures predicting FOLFIRINOX versus gemcitabine sensitivity (Tiriac 2018). Prospective trials (e.g., PASS-01, HOPE) test organoid- or signature-guided first-line choice. Turnaround (~4-6 weeks) and take rate (~70%) are the practical limits; the GATA6 classical/basal-like signature is a faster proxy.
How it works
Endoscopic biopsy or resection tissue grown in Matrigel with defined factors; dose-response to drugs read by viability assays.
- Direct functional read-out where genomics offers little
- Platform for RAS-inhibitor combination testing
- Timeline exceeds the clinical decision window for many patients
- No stroma or immune compartment
Latest papers
topQuery for this technology: (TITLE:"PDAC organoid pharmacotyping" OR ABSTRACT:"PDAC organoid pharmacotyping") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDAC organoid pharmacotyping, not a curated reading list.
Pages like this
not linked directly; found by shared links- CompanySEngine Precision Medicine
Shares Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids.
- CompanyXilis
Shares Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids.
- CompanyCuresponse
Shares Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Preclinical models that do not predict people.
- IdeaZebrafish avatars for a drug answer within a week
Shares Functional (ex vivo) drug testing, Preclinical models that do not predict people, Pancreatic ductal adenocarcinoma.
- IdeaA bone marrow niche on a chip to study human dormancy
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaTest drugs on freshly cut slices of the patient's own tumour
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- InstitutionAtrium Health Wake Forest Baptist Comprehensive Cancer Center
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaAn open organoid bank for cancers too rare to have models
Shares Cold Spring Harbor Laboratory, Patient-derived organoids, Preclinical models that do not predict people.